Services will be made available to life sciences researchers, under worldwide supply and commercialization deal.
Invitrogen will offer Cytori Therapeutics’ adipose-derived stem cell-based research products to life science investigators, through a global strategic supply and commercialization agreement. “This product offering provides life science researchers access to an important and validated stem cell population,” points out Joydeep Goswami, Ph.D., vp of stem cells and regenerative medicine for Invitrogen.
“Adipose-derived stem cells represent an attractive cell source from which to conduct regenerative medicine research,” Dr. Goswami continues. Marc H. Hedrick, M.D., president for Cytori Therapeutics, notes that, “this relationship will expand the number of therapeutic applications under development with these cells as a means to broaden the opportunities for Cytori to provide stem cell-based therapies.”
Invitrogen’s reagents that are used to isolate, characterize, expand, and differentiate stem cells will complement Cytori’s products. “Aligning ourselves with Invitrogen adds an additional partner offering Cytori’s adipose stem cells for research purposes,” says Dr. Hedrick.
